Atezolizumab plus BCG did not improve EFS compared to BCG alone in high-risk NMIBC patients. No significant differences in EFS or RFS were observed between the combination and monotherapy arms. The ...

Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...

The BCG matrix is a portfolio analysis that firms use in order to analyze the different products or services that they offer. It helps firms determine where they should be investing and where they may ...

In-depth research from Boston Consulting Group (BCG) and EcoVadis links supplier action to hard financial outcomes and puts a price on inaction Many leaders still treat decarbonisation as a compliance ...

The Middle East and Africa (MEA) space market is valued at $18 billion, according to a new report from Boston Consulting Group (BCG) titled “Governments in Space: A universe of opportunities”. The UAE ...

The global population is ageing, yet only 12 per cent of people worldwide orient their lifestyle around healthy ageing, despite a strong desire to live longer and healthier lives. Boston Consulting ...

Panelists discuss the evolving non–muscle-invasive bladder cancer (NMIBC) treatment landscape, emphasizing a shift away from BCG monotherapy for lower intermediate-risk patients toward combination and ...

The Big Three management consulting firms—McKinsey, Bain, and the Boston Consulting Group—are increasing starting salaries for MBA consultants by $15-to-$17,000 in 2023, according to a new report by ...

The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior positive feedback. The FDA has issued a refusal to file (RTF) letter for the ...

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...